Unknown

Dataset Information

0

The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.

ABSTRACT: Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, the combination of cobicistat-abacavir-rilpivirine HIV drugs demonstrated the highest in silico efficacy of inhibiting SARS-CoV-2 spike glycoprotein. Therefore, a clinical trial of cobicistat-abacavir-rilpivirine on a limited number of COVID-19 patients in moderately severe and severe condition is warranted.

SUBMITTER: Tomic D 

PROVIDER: S-EPMC7847290 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Spike glycoprotein is essential for the reproduction of the SARS-CoV-2 virus, and its inhibition using already approved antiviral drugs may open new avenues for treatment of patients with the COVID-19 disease. Because of that we analyzed the inhibition of SARS-CoV-2 spike glycoprotein with FDA-approved antiviral drugs and their double and triple combinations. We used the VINI in silico model of cancer to perform this virtual drug screening, showing HIV drugs to be the most effective. Besides, th  ...[more]

Similar Datasets

Unknown Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.
| S-EPMC7834738 | biostudies-literature
Unknown Anti-HIV drug repurposing against SARS-CoV-2.
| S-EPMC9052367 | biostudies-literature
Unknown Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro.
| S-EPMC7337386 | biostudies-literature
Unknown Computational screening for potential drug candidates against the SARS-CoV-2 main protease.
| S-EPMC7780344 | biostudies-literature
Unknown Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
| S-EPMC8579950 | biostudies-literature
Unknown Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations.
| S-EPMC9206137 | biostudies-literature
Unknown Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening.
| S-EPMC8435140 | biostudies-literature
Unknown Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
| S-EPMC10184101 | biostudies-literature
Unknown Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
| S-EPMC7826501 | biostudies-literature
Unknown Nicotine has no significant cytoprotective activity against SARS-CoV-2 infection.
| S-EPMC9387791 | biostudies-literature